<DOC>
	<DOCNO>NCT02982889</DOCNO>
	<brief_summary>This study design assess characterize safety tolerability profile LIQ865A LIQ865B formulation compare diluent aqueous bupivacaine hydrochloride infiltrate defined area medial calf , characterize bupivacaine plasma pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile single dose LIQ865A LIQ865B , determine individual plasma concentration/time curve mean PK parameter product .</brief_summary>
	<brief_title>Single Ascending Dose Study Two Liquidia Bupivacaine Formulations</brief_title>
	<detailed_description>Infiltration aqueous local anesthetic , example , bupivacaine , surgical site closure provide temporary analgesia , typically last 6 hour , one aspect multimodal approach postsurgical analgesia fast-track surgery . However , limited duration action local anesthetic , even longer act agent bupivacaine , result patient likely experience end duration breakthrough pain able take tolerate oral analgesic , thus necessitate use strong parenteral analgesic immediate postsurgical period . LIQ865A LIQ865B two distinct formulation bupivacaine manufacture via Liquidia Technologies PRINT ( Particle Replication In Non-wetting Templates ) , Liquidia intend pursue product approval . Both formulation test potential produce long-lasting control post-surgical incisional pain .</detailed_description>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>provide write informed consent prior enrollment nonsmoking male , American Society Anesthesiologist ( ASA ) physical class 1 2 BMI 18.5 25 kg . inclusive , weight least 60 kg willing able participate duration study healthy basis prestudy physical examination ( PE ) , medical history review , vital sign , lab test result specify protocol negative urine drug test result negative alcohol screen test negative antibody test result hepatitis B , hepatitis C , HIV allergic bupivacaine , amide local anesthetic , excipients LIQ865 formulation diluent take concomitant medication supplement 3 day prior Day 0 blood thinner medication affect platelet formation 7 day prior Day 0 opinion investigator , either hyper hyporesponder screen sensitivity test history moderate severe renal hepatic impairment , moderate severe active hepatic disease , clinically significant medical condition may preclude safe study participation clinically significant test result screen lab parameter history ECG screen documentation clinically meaningful conduction abnormality scarring , tattoo , infection , skin change area plan study medication injection know neurological disease dysfunction ( central peripheral ) may interfere assessment unable adequately communicate study staff , properly give informed consent , otherwise comply study procedure , particularly ability return outpatient follow visit participate another interventional clinical study ( investigational market product ) within 30 day prior Day 0 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Analytical , Diagnostic , Therapeutic Technique Equipment</keyword>
	<keyword>Anesthesia Analgesia</keyword>
</DOC>